Massimo Cristofanilli, MD, director, Breast Care Center, Jefferson University Hospitals, discusses molecular subtyping in the diagnosis and treatment of breast can
Massimo Cristofanilli, MD, director, Breast Care Center, Jefferson University Hospitals, discusses molecular subtyping in the diagnosis and treatment of breast cancer.
<<<
Everolimus Plus Lanreotide Shows PFS Benefit in Unresectable/Recurrent GEP-NETs
January 21st 2025The combination of everolimus plus lanreotide showed an improvement in progression-free survival and an acceptable safety profile vs everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.
Read More
Controversy Swirls Around the Use of CDK4/6 Inhibitors as Adjuvant Breast Cancer Therapy
January 15th 2025CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising critical questions about their clinical benefit.
Read More